 EyeGate intends to use the net proceeds to obtain additional capital to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies, though no such acquisition or in-license is current contemplated. The shares of common stock described above will be offered and sold by EyeGate pursuant to an effective shelf registration statement on Form S-3 file No. 333-231204, which was filed with the Securities and Exchange Commission the SEC on May 3, 2019 and subsequently declared effective on May 13, 2019 File No. 333-231204 the Registration Statement, and the base prospectus dated as of May 13, 2019 contained therein. 